NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Articles by Natasha Yetman
Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease
NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…
Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease
NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…
Anti-TNF Treatment Tied to Lower Risk of Acute Arterial Events in IBD
NEW YORK (Reuters Health)—Anti-tumor necrosis factor (TNF) treatment is associated with a reduced risk of acute arterial events in patients with inflammatory bowel disease (IBD), especially men, new research shows. IBD patients face an increased risk of acute arterial events, which are also independently associated with disease activity, Julien Kirchgesner, MD, PhD, of Hospital Saint-Antoine,…
Healthcare Data Hacking May Lead to Identity Thefts
(Reuters Health)—More than 70% of healthcare data breaches in the U.S. have involved sensitive demographic or financial information that could fuel identity theft, a new study suggests. When a healthcare company is hacked, criminals gain access not only to health information, but also to demographic and financial data that could compromise patients’ privacy and financial…
Dual-Energy CT May Help Detect Gout Patients at Risk for Heart Disease
NEW YORK (Reuters Health)—Dual energy computed tomography (DECT) can differentiate cardiovascular monosodium urate (MSU) deposits from calcium deposits in patients with gout, potentially identifying those at risk of heart disease, researchers say. Sylvia Strobl, MD, of Medical University Innsbruck and colleagues analyzed calcium scores and MSU deposits in 59 patients with gout (mean age: 59;…
Obesity, Drinking & Unhealthy Diet Add to Gout Risk
(Reuters Health)—Behavior changes could potentially reduce a large part of the risk for developing gout, a U.S. study suggests. Based on data from more than 14,000 people, researchers calculated how much factors like being overweight, following a diet that isn’t heart healthy, drinking alcohol or taking diuretics contribute to high levels of uric acid—a precursor…
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
Osteoporosis Drugs Don’t Reduce Overall Mortality
NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…
Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads
(Reuters)—The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements. The U.S. Department of Health and Human Services (HHS) filed a notice of appeal on Wednesday, as it prepares to challenge the July federal court ruling. “If the…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 97
- Next Page »